ReJoin® Therapy for Knee Osteoarthritis
Phase IIb Trial Completed
Our ReJoin® human adipose-derived mesenchymal progenitor cell (haMPC) therapy for KOA is an interventional therapy that consists of adipose (fat) tissue obtained from the patient, and are then expanded using CBMG’s proprietary culture medium (serum-free and antibiotics-free), and formulated for ReJoin® therapy using CBMG’s proprietary formulation.
|Name of Study||Autologous Adipose Tissue Derived Mesenchymal Progenitor Cells Therapy for Patients With Knee Osteoarthritis|
|Phase||Clinical Trial IIb|
48 Week Follow-Up Data - Cartilage regrowth as early as 3 months - VIEW HERE
|ClinicalTrials.gov Identifier||NCT02162693 - view study online here|
|Study Design||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
|Principal Investigator||Chunde Bao, MD|
|Hospital(s)||Shanghai Renji Hospital|
CBMG, in partnership with Renji Hospital affiliated with Shanghai Jiaotong University, completed a Phase I/IIa clinical trial in using haMPC’s to apply to KOA indications according to Chinese regulatory requirements.